Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
IP lawyers at three firms reflect on how courts across Australia have reacted to AI use in litigation, and explain why they support measured use of the technology
Noemi Parrotta, chair of the European subcommittee within INTA's International Amicus Committee, explains why the General Court’s decision in the Iceland case could make it impossible to protect country names as trademarks
Inès Garlantezec, who became principal of the firm’s Luxembourg office earlier this year, discusses what's been keeping her busy, including settling a long-running case
In the sixth episode of a podcast series celebrating the tenth anniversary of IP Inclusive, we discuss IP Futures, a network for early-career stage IP professionals